Aurobindo Pharma channelising efforts to commercialise COVID-19 vaccine

Drug major Aurobindo Pharma is looking to commercialise a COVID-19 vaccine, build a portfolio of biosimilar products, expand API production as part of its growth plans going ahead, as per company's annual report for 2020-21. The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fy0JG6
via IFTTT